Marc Wilson has sold CRNX and made no open-market buys since Jun 2023

Marc Wilson is a corporate finance executive and certified public accountant who served as Chief Financial Officer of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) from January 2018 through February 2025.( During his tenure, he oversaw the company’s finance and accounting functions as Crinetics advanced its rare disease endocrine therapeutics portfolio and navigated key growth milestones, including equity financing activities and ongoing SEC reporting as a public company.( Following his CFO role, Wilson transitioned to an independent consultant position with Crinetics beginning April 2025, providing advisory services on accounting and finance matters through April 2026.(

Before joining Crinetics, Wilson was Vice President of Finance and Accounting and Chief Accounting Officer at Cidara Therapeutics, where he led accounting and finance from post–Series A financing through the company’s initial public offering.( Earlier, he served as Director of Accounting and Controller at Trius Therapeutics until its acquisition by Cubist Pharmaceuticals, and held finance roles at Neurocrine Biosciences after starting his career at PricewaterhouseCoopers LLP.( Wilson is a certified public accountant and earned a bachelor’s degree in economics and accounting from the College of the Holy Cross, grounding his executive leadership in a strong technical and analytical foundation.( Recent SEC filings and market reports identify him as a corporate insider in connection with option exercises and share sales in Crinetics Pharmaceuticals common stock.(

Written by Perplexity from public sources.